NASDAQ: ALDX
Aldeyra Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for ALDX

Based on 1 analyst offering 12 month price targets for Aldeyra Therapeutics Inc

Min Forecast
$2.00+49.25%
Avg Forecast
$2.00+49.25%
Max Forecast
$2.00+49.25%

Should I buy or sell ALDX stock?

Based on 1 analyst offering ratings for Aldeyra Therapeutics Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ALDX's forecast from analysts indicates a "Hold", our proven Zen Rating quant model rates ALDX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their ALDX stock forecasts and price targets.

ALDX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-18

1 of 1

Forecast return on equity

Is ALDX forecast to generate an efficient return?

Company
247.69%
Industry
20.5%
Market
167.71%
ALDX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ALDX forecast to generate an efficient return on assets?

Company
197.38%
Industry
23.66%
ALDX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALDX earnings per share forecast

What is ALDX's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.35
Avg 2 year Forecast
-$0.28
Avg 3 year Forecast
-$0.15

ALDX revenue forecast

What is ALDX's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$6.9M
Avg 3 year Forecast
$27.3M

ALDX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALDX$1.34$2.00+49.25%Hold
TELO$1.17N/AN/A
KLRS$3.38$18.67+452.28%Strong Buy
RNXT$1.76$8.75+397.16%Buy
MAIA$1.30N/AN/A

Aldeyra Therapeutics Stock Forecast FAQ

Is Aldeyra Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ALDX) stock is to Hold ALDX stock.

Out of 1 analyst, 0 (0%) are recommending ALDX as a Strong Buy, 0 (0%) are recommending ALDX as a Buy, 1 (100%) are recommending ALDX as a Hold, 0 (0%) are recommending ALDX as a Sell, and 0 (0%) are recommending ALDX as a Strong Sell.

If you're new to stock investing, here's how to buy Aldeyra Therapeutics stock.

What is ALDX's earnings growth forecast for 2026-2028?

(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.8%.

Aldeyra Therapeutics's earnings in 2026 is -$23,052,740.On average, 7 Wall Street analysts forecast ALDX's earnings for 2026 to be -$20,921,203, with the lowest ALDX earnings forecast at -$23,056,758, and the highest ALDX earnings forecast at -$19,636,250. On average, 7 Wall Street analysts forecast ALDX's earnings for 2027 to be -$17,108,573, with the lowest ALDX earnings forecast at -$23,647,957, and the highest ALDX earnings forecast at -$10,134,839.

In 2028, ALDX is forecast to generate -$8,922,278 in earnings, with the lowest earnings forecast at -$15,962,371 and the highest earnings forecast at -$1,266,855.

What is ALDX's revenue growth forecast for 2026-2028?

(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.22%.

Aldeyra Therapeutics's revenue in 2026 is $0.On average, 7 Wall Street analysts forecast ALDX's revenue for 2026 to be $0, with the lowest ALDX revenue forecast at $0, and the highest ALDX revenue forecast at $0. On average, 7 Wall Street analysts forecast ALDX's revenue for 2027 to be $413,477,290, with the lowest ALDX revenue forecast at $0, and the highest ALDX revenue forecast at $1,304,679,507.

In 2028, ALDX is forecast to generate $1,646,669,988 in revenue, with the lowest revenue forecast at $679,878,765 and the highest revenue forecast at $2,661,782,674.

What is ALDX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ALDX) forecast ROA is 197.38%, which is higher than the forecast US Biotechnology industry average of 23.66%.

What is ALDX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ALDX price target, the average ALDX price target is $2.00, with the highest ALDX stock price forecast at $2.00 and the lowest ALDX stock price forecast at $2.00.

The Wall Street analyst predicted that Aldeyra Therapeutics's share price could reach $2.00 by Mar 18, 2027. The average Aldeyra Therapeutics stock price prediction forecasts a potential upside of 49.25% from the current ALDX share price of $1.34.

What is ALDX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ALDX) Aldeyra Therapeutics's current Earnings Per Share (EPS) is -$0.38. On average, analysts forecast that ALDX's EPS will be -$0.35 for 2026, with the lowest EPS forecast at -$0.38, and the highest EPS forecast at -$0.33. On average, analysts forecast that ALDX's EPS will be -$0.28 for 2027, with the lowest EPS forecast at -$0.39, and the highest EPS forecast at -$0.17. In 2028, ALDX's EPS is forecast to hit -$0.15 (min: -$0.26, max: -$0.02).

What is ALDX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ALDX) forecast ROE is 247.69%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.